<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01122381</url>
  </required_header>
  <id_info>
    <org_study_id>B5043-R</org_study_id>
    <nct_id>NCT01122381</nct_id>
  </id_info>
  <brief_title>Comparison of a Drug and Placebo in the Prevention of Migraine Headaches</brief_title>
  <official_title>Pharmacologic and Genetic Evaluation of a C. Elegans Model for Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ethosuximide works better than placebo in
      the prevention of episodic migraine among veterans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic and episodic headaches in veteran populations include migraine, transformed migraine,
      and post-traumatic headache with migrainous features. More and better prophylactic drugs with
      fewer side effects (such as weight gain) are needed to treat these disabling, refractory
      conditions which generally have less than a 50% response rate to preventative treatments.

      Rare forms of severe familial hemiplegic migraine (FHM) are considered channelopathies and
      can be caused by mutations in a calcium channel gene. Serotonin is also known to be a
      critical neurotransmitter in migraine based on the pharmacology of acute and preventative
      treatments. We previously identified a &quot;migraine&quot; signaling pathway in an invertebrate C.
      elegans &quot;hemiplegic migraine&quot; model of a mutant calcium channel upstream from transforming
      growth factor-beta (TGF-beta) and showed that low serotonin levels can be rescued by
      treatment with the childhood antiepileptic drug ethosuximide (ESX).

      Objective: We propose to test our findings from this invertebrate migraine model to determine
      its relevance to humans in the prevention of episodic migraine.

      Primary Aim: Determine whether ethosuximide (ESX) will be significantly more effective than
      placebo in reducing migraine headache days. We propose a 3 year, double blind, phase 1/2
      randomized, 2:1 ESX:placebo controlled parallel trial in episodic migraineurs comparing
      migraine headache days during the last 4 weeks of treatment to a pre-treatment 4 week
      baseline.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor recruitment
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Migraine Headache Days Per 4 Week Period Comparing the Last 4 Weeks of Treatment to a 4 Week Pre-treatment Baseline.</measure>
    <time_frame>4 weeks, end of treatment and pre-treatment baseline</time_frame>
    <description>Compare number of migraine headache days pre and post treatment between the ESX and placebo group.
Study terminated early-no outcome data available. The single subject assigned to study drug did not actually take it according to subsequent review of ESX drug levels.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Headache, Migraine</condition>
  <arm_group>
    <arm_group_label>Arm 1-ethosuximide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ethosuximide blinded capsules of 250mg ESX; titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed &quot;30mg&quot;/kg/d) vs maximum tolerability</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2-placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo same size blinded capsules as the 250mg ESX; similar titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed &quot;30mg&quot;/kg/d) vs maximum tolerability</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ethosuximide</intervention_name>
    <description>ethosuximide (ESX)</description>
    <arm_group_label>Arm 1-ethosuximide</arm_group_label>
    <other_name>zarontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo comparator</intervention_name>
    <description>placebo</description>
    <arm_group_label>Arm 2-placebo comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be a veteran.

          -  The number of migraine days per 4-week period is to be 4-14 for a period of 3 months
             prior to screening for entry into the trial.

          -  Migraine must have been occurring for 6 months preceding entry into the trial and age
             of onset should be before age 60 years.

          -  Migraine must be at least moderate severity and interrupt daily activities in some
             respect at least 3 times per month.

          -  As long as the veteran can easily distinguish nonmigraine headaches from migraine,
             there is no limit on the number of non migraine headache days allowed. &quot;Transformed
             migraine&quot; headaches due to medication over usage will be excluded according to
             exclusion criteria #4.

          -  Migraine diagnosis:

        Veterans with headache must have migraine categorized using the International Headache
        Society (I.H.S.) criteria as illustrated below for the two main types with and without
        aura.

        Criteria for migraine without aura (I.H.S. 1.1)

          -  &gt; 5 attacks

          -  headache lasting 4-72 hours when untreated or not successfully treated.

          -  headache with two of the following characteristics

               -  unilateral,

               -  pulsating,

               -  moderate to severe intensity,

               -  aggravation by exertion.

          -  one of the following occurs with headache

               -  nausea and/or vomiting

               -  photophobia and phonophobia

        Criteria for migraine with aura (I.H.S. 1.2)

          -  at least 2 attacks

          -  at least three of the following characteristics:

               -  One or more fully reversible aura symptoms indicating focal cerebral cortical -
                  and/or brain stem dysfunction.

        One or more aura symptoms of the following types:

          -  Homonymous visual disturbance

          -  Unilateral parenthesis and/or numbness

          -  Unilateral weakness

          -  Aphasia or unclassifiable speech difficulty

               -  At least one aura symptom develops gradually over more than 4 minutes or, 2 or
                  more symptoms occur in succession.

               -  No aura symptom lasts more than 60 minutes. If more than one aura symptom is
                  present, accepted duration is proportionally increased.

               -  Headache follows aura with a free interval of less than 60 minutes. (It may also
                  begin before or simultaneously with the aura). Headache, nausea and/or
                  photophobia usually follow neurological aura symptoms directly or after a free
                  interval of less than an hour. The headache usually lasts 4-72 hours, but may be
                  completely absent (1.2.5, acephalgic migraine).

        Exclusion Criteria:

          -  Veterans with migraine plus other systemic disorder will be excluded if migraine onset
             was temporally related to onset of the systemic disorder.

          -  Blood pressure elevations (must be &lt; borderline values 135/85 for 4 weeks before
             enrollment into the study). Current treatment for hypertension with beta-blockers,
             calcium channel blockers, or ace inhibitors not allowed.

          -  Use of other prophylactic migraine drugs (requires a washout phase) and cannot have
             failed more than two other prophylactic drugs for migraine.

          -  Excessive use of acute pain medicines, including narcotics (&gt;10 days month). Those
             using non-narcotics could be tapered off over 4-8 weeks.

          -  Receiving disability or seeking disability for headache or chronic pain.

          -  Significant neck pain or cervicogenic contributors to chronic headache.

          -  Significant depression, anxiety, post-traumatic stress disorder, or other disabling
             psychiatric condition.

          -  Known allergies or serious side effects with ESX or succinimides in the past.

          -  Known liver or significant renal disease.

          -  Women veterans of child-bearing age who do not have adequate birth control.

          -  Chronic bone marrow suppression.

          -  Using psychogenic or other sedating maintenance drugs.

          -  History of porphyria.

          -  History of cluster headache. 15.History of other CNS disease.

          -  Age younger than 18 years and greater than 65.

          -  Women veterans who are breastfeeding.

          -  Veterans with familial hemiplegic migraine (FHM).

        Ongoing exclusions during the study:

          -  The addition of other migraine prophylactic headache medicines is not allowed. 2. New
             drugs cannot be added that aggravate headache (nitrates, dipyridamole, niacin).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathy L Gardner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Pittsburgh Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Pittsburgh Health Care System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2010</study_first_submitted>
  <study_first_submitted_qc>May 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2010</study_first_posted>
  <results_first_submitted>June 5, 2015</results_first_submitted>
  <results_first_submitted_qc>August 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 19, 2015</results_first_posted>
  <last_update_submitted>August 11, 2015</last_update_submitted>
  <last_update_submitted_qc>August 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>headache, migraine</keyword>
  <keyword>depression</keyword>
  <keyword>disability evaluation</keyword>
  <keyword>weight gain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethosuximide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Primary Care and Neurology Clinic prescreening and recruitment from VA Pittsburgh hospitals during the following periods:
1/14/11-4/1/11; 1/14/12-3/19/12; 2/4/13-3/12/14. Average prescreening of datawarehouse records for eligibility = 2954 subjects/month.
Average prescreening electronic chart review for eligibility = 265 subjects/month.</recruitment_details>
      <pre_assignment_details>5 consented. Initial 4 week baseline period uses headache diary to confirm headache days prior to randomization. 3/5 enrollees did not begin baseline phase; 1 lost to f/u, 1 dis-enrolled due to study interruption, 1 dis-enrolled shortly after consent when another physician began a study excluded drug. 2 enrollees did complete baseline phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1-drug Treatment</title>
          <description>migraineurs with 4-14 headache days per month that meet all inclusion/exclusion criteria
ethosuximide: ethosuximide (ESX) 250mg blinded capsules; begin 250mg qd titrating up to 1000mg qd (expected) or 1250mg qd, or 1500mg qd /30mg/kg/d maximum for efficacy goal of &lt; 50% reduction in headache days versus maximum tolerability</description>
        </group>
        <group group_id="P2">
          <title>Arm 2-placebo</title>
          <description>migraineurs with 4-14 headache days per month that meet all inclusion/exclusion criteria
placebo comparator: placebo same size blinded capsules as the 250mg ESX; similar titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed 30mg/kg/d) vs maximum tolerability</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1">Subject never took the drug per review of ESX levels after unblinding</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>study terminated early</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Enrollees who completed baseline period and randomization.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>migraineurs with 4-14 headache days per month that meet all inclusion/exclusion criteria
ethosuximide: ethosuximide (ESX) 250mg blinded capsules; begin 250mg qd titrating up to 1000mg qd (expected) or 1250mg qd, or 1500mg qd /30mg/kg/d maximum for efficacy goal of &lt; 50% reduction in headache days versus maximum tolerability</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>placebo same size blinded capsules as the 250mg ESX; similar titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed &quot;30mg&quot;/kg/d) vs maximum tolerability
placebo comparator: placebo same size blinded capsules as the 250mg ESX; similar titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed 30mg/kg/d) vs maximum tolerability</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Migraine Headache Days Per 4 Week Period Comparing the Last 4 Weeks of Treatment to a 4 Week Pre-treatment Baseline.</title>
        <description>Compare number of migraine headache days pre and post treatment between the ESX and placebo group.
Study terminated early-no outcome data available. The single subject assigned to study drug did not actually take it according to subsequent review of ESX drug levels.</description>
        <time_frame>4 weeks, end of treatment and pre-treatment baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1-ethosuximide</title>
            <description>Study was terminated early-no outcome data available. Only one subject was assigned to study drug arm but did not actually take it according to subsequent review of ESX drug levels.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2-placebo Comparator</title>
            <description>Study was terminated early-no outcome data available. Only one subject was assigned to study placebo but was dis-enrolled after titration phase due to study termination.</description>
          </group>
        </group_list>
        <measure>
          <title>Migraine Headache Days Per 4 Week Period Comparing the Last 4 Weeks of Treatment to a 4 Week Pre-treatment Baseline.</title>
          <description>Compare number of migraine headache days pre and post treatment between the ESX and placebo group.
Study terminated early-no outcome data available. The single subject assigned to study drug did not actually take it according to subsequent review of ESX drug levels.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1- Ethosuximide</title>
          <description>ethosuximide blinded capsules of 250mg ESX; subject was titrated up to 4 capsules qd</description>
        </group>
        <group group_id="E2">
          <title>Arm 2- Placebo Comparator</title>
          <description>placebo blinded capsules of &quot;250mg&quot;; subject was titrated up to 4 capsules qd</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>grade 1, mild</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <description>grade 1, mild</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <description>grade 1, mild</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <description>grade 1, mild</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>somnolence</sub_title>
                <description>grade 1, mild</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>hiccups</sub_title>
                <description>grade 1, mild</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination occurred due to inadequate recruitment of episodic migraineurs in a population meeting too many exclusion criteria; resulting in no subjects available for analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kathy Gardner MD</name_or_title>
      <organization>Vetarans Administration Pittsburgh Healthcare System</organization>
      <phone>(412) 360-6185</phone>
      <email>kathy.gardner@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

